BAFNA PHARMACEUTICALS LTD. - 532989 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith Certificate dated 4th April 2022 issued by Cameo Corporate Services Limited, Registrar and Transfer Agent (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. BAFNA PHARMACEUTICALS LTD. - 532989 - Certificate From Practicing Company Secretary For The Half Year Ended 31St March 2022
Certificate from Practicing Company Secretary under Regulation 40(9) of SEBI (LODR) Regulations, 2015 for the half year ended 31st March 2022 is hereby enclosed for your reference. BAFNA PHARMACEUTICALS LTD. - 532989 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Roopa RavikumarDesignation :- Company Secretary and Compliance Officer BAFNA PHARMACEUTICALS LTD. - 532989 - Compliance Certificate For The Half Year Ended 31St March 2022
Compliance Certificate that all activities in relation to share transfer facility are maintained by Registrar to an issue and share transfer agent registered with the Board under Regulation 7(3) of SEBI (LODR) Regulations, 2015 for the half year ended 31st March 2022 is hereby enclosed for your reference. BAFNA PHARMACEUTICALS LTD. - 532989 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayBAFNA PHARMACEUTICALS LTD. 2CINL24294TN1995PLC030698 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 4.27 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Roopa Ravikumar Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: MELAGIRI SRIDHAR Designation: CHIEF FINANCIAL OFFICER EmailId: [email protected] Date: 05/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. BAFNA PHARMACEUTICALS LTD. - 532989 - Closure of Trading Window
We wish to inform you that pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the Securities of the Company will be closed from April 01, 2022 till Forty-Eight (48) hours after the declaration of Standalone Financial Results of the Company for the Quarter and Year ending on March 31, 2022 The date of Board Meeting for consideration & approval of the Standalone Financial Results of the Company for the Quarter and Year ending on March 31, 2022 will be intimated in due course. BAFNA PHARMACEUTICALS LTD. - 532989 - Appointment of Company Secretary and Compliance Officer
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A of Schedule III of said Regulations, this is to inform you that the Board of Directors in its meeting held today i.e. 21st March 2022 , considered and approved the appointment of Mrs. Roopa Ravikumar (Membership No: F11282) as Company Secretary & Compliance officer of the Company w.e.f 22nd March 2022. BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A of Schedule III of said Regulations, this is to inform you that the Board of Directors in its meeting held today i.e. 21st March 2022 , considered and approved the resignation by Mr. Jitendra Kumar Pal from the post of Company Secretary & Compliance officer of the Company due to personal reasons with effect from closure of business hours on 21st March 2022 BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Outcome for Outcome Of Board Meeting Held On 21St March 2022
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A of Schedule III of said Regulations, this is to inform you that the Board of Directors in its meeting held today i.e. 21st March 2022 , considered and approved the following: 1. Resignation by Mr. Jitendra Kumar Pal from the post of Company Secretary & Compliance officer of the Company due to personal reasons with effect from closure of business hours on 21st March 2022. 2.. Appointment of Mrs. Roopa Ravikumar (Membership No: F11282) as Company Secretary & Compliance officer of the Company w.e.f 22nd March 2022 BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for To Consider Resignation And Appointment Of Company Secretary (KMP) Of The Company And Any Other Business With The Permission Of Chair.
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/03/2022 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Monday, 21st day of March 2022 online through zoom video conferencing, at 11.00 A.M to inter alia consider resignation and appointment of Company Secretary (KMP) of the Company and any other business with the permission of chair.